ALNY News and Press, Alnylam Pharmaceuticals Inc. From 06/15/22

Bank of America has opened a 90-day catalyst watch for Alnylam Pharmaceuticals as the RNAi therapeutics company plans to share topline data from a late-stage trial for experimental therapy patisiran in ATTR amyloidosis with cardiomyopathy (ATTR-CM). Patisiran is marketed as Onpattro in the U....

The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals' (NASDAQ:ALNY) RNAi therapy Amvuttra (vutrisiran) to treat polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. The approval comes almost a month early from the date set by the FDA, afte...

– First and Only FDA-approved Treatment Demonstrating Reversal in Neuropathy Impairment with Subcutaneous Administration Once Every Three Months – – AMVUTTRA Met Primary and All Secondary Endpoints, with Significant Improvement in Polyneuropathy, Quality o...

Alnylam Pharmaceuticals (NASDAQ:ALNY), a biotech focused on RNA interference, announced Thursday that its experimental RNAi therapy cemdisiran caused a 37% mean reduction of an important indicator of disease progression in immunoglobulin A nephropathy ((IgAN)). Alnylam (ALNY) has partnered wi...

- Cemdisiran Treatment Resulted in a 37 Percent Mean Reduction in 24-Hour Urine Protein to Creatinine Ratio , Relative to Placebo – a Key Prognostic Marker of Progression to End-Stage Kidney Disease in Patients with IgA Nephropathy - - Acceptable Safety Prof...

Brokerage William Blair on Tuesday initiated an outperform rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock, while estimating a fair value for the shares of $190, which represents a 44.3% upside to the stock's last closing price of $131.63. "The company has been led by a quality manageme...

Alnylam Pharmaceuticals (NASDAQ:ALNY) said new analysis from a late-stage study of its drug Oxlumo (lumasiran) showed that the drug helped improve cardiac measures, calcium deposit levels and kidney stone events in patients with advanced primary hyperoxaluria type 1 (PH1). PH1 is a ...

– Lumasiran Demonstrated Evidence of Improvements in Exploratory Endpoints of Systemic Oxalosis, Including Echocardiographic Structure and Function, Nephrocalcinosis, and Kidney Stone Events – – Expands Upon Previously Reported Reductions in Plasma Oxalate...

– New Exploratory Findings from 18-Month Analysis of HELIOS-A Suggest that Treatment with Investigational Vutrisiran May Benefit Patients with Hereditary ATTR (hATTR) Amyloidosis and Cardiac Involvement – – Improvements in NT-proBNP and Echocardiographic P...

Alnylam Pharmaceuticals (NASDAQ:ALNY) said Health Canada issued a notice of compliance (NOC) authorizing its Oxlumo (lumasiran) injection for subcutaneous use as a therapy for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adult patients. PH1 is a rare...